• Anavex posted fiscal Q3 net income of $7.8 million, or $0.08 a share, versus a $13.2 million loss.
• Operating income was $6.7 million, swinging from a $14.5 million operating loss, on stock-based compensation reversals tied to employee terminations.
• Cash and cash equivalents rose to $118.3 million at June 30, 2026; funding runway expected into mid to late fiscal 2028.
• Alzheimer’s: submitted all clinical trial data to a newly opened IND; plans FDA talks on Phase 3 design for ANAVEX2-73-AD-005.
• Rett: filed FDA meeting request to add pediatric patients to Phase 3 ANAVEX2-73-RS-005; Fragile X IND submission targeted for September.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250800PRIMZONEFULLFEED9815355) on August 25, 2026, and is solely responsible for the information contained therein.